Core Viewpoint - Wanbangde's subsidiary has been selected for a significant national project focused on innovative drug development for Alzheimer's disease, indicating a strategic advancement in the company's research capabilities [1] Group 1 - Wanbangde Pharmaceutical Group has been awarded a project under the National Major Science and Technology Project for Innovative Drug Development led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences [1] - The project has received formal approval from the National Health Commission's China Biotechnology Development Center, highlighting governmental support for the initiative [1]